Navigation Links
Crux Biomedical Named One of Top 50 Companies to Watch
Date:7/12/2010

MENLO PARK, Calif., July 12 /PRNewswire/ -- Crux Biomedical® was named one of "50 Companies to Watch" in an annual survey of medical device and diagnostic companies. The survey, conducted by Medical Device and Diagnostics Industry (MD+DI), was published in its June 2010 issue. The purpose of the survey was to identify firms that have either achieved success or have the potential to revolutionize medical practice with their respective products.

Crux Biomedical, founded in 2004 by Dr. Thomas Fogarty, has targeted the development of an advanced implantable vena cava filter (VCF) to prevent the occurrence of a potentially fatal  pulmonary embolism (PE).  Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. This is more than the combined deaths associated with breast cancer, highway fatalities and AIDS. The U.S. market for VCFs  is valued at $300MM and growing between 8-10% annually.

Although routinely used in the United States, currently cleared vena cava filters are associated with a variety of complications including filter tilt and retrieval difficulty. The  Crux VCF is designed to address limitations of currently available VCFs.  "The Crux VCF is designed to self-center in the vena cava and has the advantage of retrievability from either the femoral or jugular approach," stated Eric Johnson, V.P., R&D of Crux Biomedical.

Crux Biomedical is currently enrolling patients in its pivotal IDE study in the United States and several international locations. It expects to complete enrollment by the end of 2010. "We are very pleased with the initial physician response to the Crux Biomedical Vena Cava Filter and believe our device will better meet the needs of implanting physicians," stated Mel Schatz, CEO of Crux Biomedical.

The firm is located in Menlo Park, California and is privately funded by Alloy Ventures and Emergent Medical Partners.


'/>"/>
SOURCE Crux Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
2. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
3. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
4. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
7. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
8. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
11. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):